• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION SYNERGY MEGATRON; CORONARY DRUG-ELUTING STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION SYNERGY MEGATRON; CORONARY DRUG-ELUTING STENT Back to Search Results
Lot Number 0028391612
Device Problems Difficult or Delayed Positioning (1157); Device Dislodged or Dislocated (2923)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 03/28/2023
Event Type  malfunction  
Event Description
It was reported that the stent moved on balloon.The patient presented for percutaneous coronary intervention (pci) of the target lesion located in the right coronary artery (rca) ostium.A 4.00 x 32mm synergy megatron drug-eluting stent was advanced for treatment.However, before deploying the stent, the physician noticed that the distance between the distal marker and stent edge versus the proximal marker and proximal stent edge were not the same, and the physician had a hard time deploying the stent.The procedure was completed successfully.No patient complications were reported.
 
Manufacturer Narrative
Initial reporter address 2: (b)(6).
 
Manufacturer Narrative
E1 - initial reporter address 2: (b)(6).The device was not returned for analysis; therefore, a technical analysis could not be performed.An image provided by the site was examined by boston scientific medical personal.Based on their assessment, the image was consistent with the reported event.The inconsistent markerband gap lengths were likely caused by megatron movement on the stent delivery system (sds) during delivery to the target lesion.
 
Event Description
It was reported that the stent moved on balloon.The patient presented for percutaneous coronary intervention (pci) of the target lesion located in the right coronary artery (rca) ostium.A 4.00 x 32mm synergy megatron drug-eluting stent was advanced for treatment.However, before deploying the stent, the physician noticed that the distance between the distal marker and stent edge versus the proximal marker and proximal stent edge were not the same, and the physician had a hard time deploying the stent.The procedure was completed successfully.No patient complications were reported.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNERGY MEGATRON
Type of Device
CORONARY DRUG-ELUTING STENT
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
300 boston scientific way
marlborough MA 01752
Manufacturer (Section G)
BOSTON SCIENTIFIC CORPORATION
ballybrit business park
galway
EI  
Manufacturer Contact
jeff wallner
4100 hamline ave n
arden hills, MN 55112
6515811560
MDR Report Key16735501
MDR Text Key313247685
Report Number2124215-2023-16498
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)Y
Reporter Country CodeMY
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 05/15/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received04/13/2023
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date10/27/2023
Device Lot Number0028391612
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received05/05/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured10/27/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Age67 YR
Patient SexMale
Patient RaceAsian
-
-